Your fact-checks will appear here
Kidney cancer that is found in the kidney and is usually found before birth by ultrasound or within the first 3 months of life
Available reporting shows no clinical trials of a product named “Memoblast” or “MemoBlast”; instead the search results center on Mesoblast — an established cellular-therapy company whose trials of mes...
There are two distinct products in the available reporting that resemble the name “memoblast”: Ryoncil (Mesoblast’s mesenchymal stromal cell product) which has documented serious adverse events includ...
Available reporting on “Memoblast” — a name that appears variably as “MemoBlast” (dietary supplement) and is easily confusable with Mesoblast/Remestemcel‑L (cell therapy) — is sparse and fragmented in...
Remestemcel‑L, marketed as Ryoncil, is an allogeneic bone‑marrow‑derived mesenchymal stromal cell (MSC) therapy approved by the U.S. Food and Drug Administration to treat steroid‑refractory acute graf...
MemoBlast (sometimes written “Memo Blast” or “MemoBlast™”) is marketed as an over‑the‑counter dietary nootropic sold to bolster memory, focus and “brain health,” with claims coming from product websit...
Mesoblast, an Australian biopharmaceutical company, is the developer behind the cellular therapy programs that are most likely meant by “Memoblast” — the company’s product families include remestemcel...
Two distinct products appear under the “Memoblast/MemoBlast” name in the supplied reporting, and their safety evidence is not interchangeable: an investigational mesenchymal cell therapy for degenerat...
Mesoblast is a developer and now commercial seller of allogeneic (off‑the‑shelf) mesenchymal lineage cell therapies, led by the FDA‑approved product Ryoncil® (remestemcel‑L) for steroid‑refractory acu...
Available reporting shows Mesoblast has conducted multiple Phase 3 trials of its cell‑therapy candidates (including rexlemestrocel‑L/revascor/rexlemestrocel‑L variants) and at least one Phase 3 trial ...
Available reporting on “MemoBlast” products is mixed: official and retail pages repeatedly claim “no significant side effects” or safety for broad audiences , while independent or clinic-hosted pages ...
Mesoblast’s remestemcel‑L (branded Ryoncil) has received U.S. FDA approval for pediatric steroid‑refractory acute graft‑versus‑host disease (SR‑aGvHD), according to multiple reports citing a December ...
Memoblast (remestemcel‑L, marketed as Ryoncil®/RYONCIL®/Ryoncil in Mesoblast materials) is an allogeneic bone‑marrow derived mesenchymal stromal cell therapy. The U.S. FDA granted approval for remeste...
A review of the provided reporting finds multiple peer‑reviewed clinical trials and published trial results for Mesoblast cell‑therapy products (for example trials of rexlemestrocel‑L and remestemcel‑...
Mesoblast’s Memoblast program (rexlemestrocel-L / MPC-06-ID) set a 12‑month pain reduction composite as the next Phase 3 primary objective: a 50% reduction in low back pain plus a 15‑point improvement...
The FDA’s earlier complete response letters (CRLs) for Mesoblast’s remestemcel‑L (Ryoncil) centered on two buckets of concern: the adequacy of clinical evidence—specifically a preference for randomize...
The U.S. Food and Drug Administration reviewed and granted approval to Mesoblast’s remestemcel‑L, branded Ryoncil, for steroid‑refractory acute graft‑versus‑host disease (SR‑aGVHD) in pediatric patien...
The term "memoblast" in the returned search results appears in two distinct contexts: as part of Mesoblast, a well‑known Australian cellular‑therapy company (multiple investor and press items) and as ...
There is no evidence in the supplied reporting or patent records that a molecule, drug, company product or intellectual property formally named “memoblast” appears in peer‑reviewed scientific literatu...
Available reports about Mesoblast’s lead MSC products (remestemcel‑L / Ryoncil and rexlemestrocel‑L / Revascor) document serious adverse reactions in trials—most commonly infections, fever, hemorrhage...
Mesoblast’s rexlemestrocel-L (Revascor®/Rexlemestrocel-L) and remestemcel-L (Ryoncil/Remestemcel‑L) are active in late‑stage and post‑approval development across multiple indications; Mesoblast is pur...